Other recent studies have shown that STAT3 activation via JAK1 kinase activity in primary murine und human CML cells persists despite TKI therapy [87], and upon in vivo TKI treatment, STAT3 expression is upregulated in human CD34+ CML cells. The gene discussed is JAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.